Lyell Immunopharma (LYEL) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$34.0 million.
- Lyell Immunopharma's Income towards Parent Company rose 2369.33% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 7161.37%. This contributed to the annual value of -$334.7 million for FY2024, which is 4971.13% down from last year.
- According to the latest figures from Q3 2025, Lyell Immunopharma's Income towards Parent Company is -$34.0 million, which was up 2369.33% from -$43.9 million recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's Income towards Parent Company ranged from a high of -$11.3 million in Q4 2022 and a low of -$196.2 million during Q4 2024
- Over the past 5 years, Lyell Immunopharma's median Income towards Parent Company value was -$52.4 million (recorded in 2023), while the average stood at -$57.0 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 7600.13% in 2022, then plummeted by 36266.0% in 2023.
- Quarter analysis of 5 years shows Lyell Immunopharma's Income towards Parent Company stood at -$47.2 million in 2021, then skyrocketed by 76.0% to -$11.3 million in 2022, then tumbled by 362.66% to -$52.4 million in 2023, then tumbled by 274.31% to -$196.2 million in 2024, then soared by 82.68% to -$34.0 million in 2025.
- Its last three reported values are -$34.0 million in Q3 2025, -$43.9 million for Q2 2025, and -$53.5 million during Q1 2025.